Investigation of Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic Disorders (NeuroSplitsz)
Primary Purpose
Schizophrenia
Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
compare the two groups of schizophrenic patients
compare the two groups of schizophrenic patients versus volunteers
Sponsored by
About this trial
This is an interventional treatment trial for Schizophrenia
Eligibility Criteria
Inclusion Criteria:
- for both patients and controls
- male or female willing to participate and who have signed up the legal document
- under the protection of health insurance for patients only
- schizophrenia or schizo-affective disorder according to the DSM-5 criteria
- periodic catatonia or hebephrenia accordin to WKL classification
- clinically stable for at least 2 months
- in or out patients for controls only
- no psychiatric history
Exclusion Criteria:
- for both patients and controls
- current severe or unstable somatic illness
- neurological history (epilepsia, brain injury, brain surgery…)
- current substance use disorder (DSM-5)
- current major depressive disorder (DSM-5)
- mental retardation (IQ < 70)
- pregnancy, breast feeding
- current legal control
- contra-indication for fMRI for controls only psychotropic intake during the last 3 weeks
Sites / Locations
- Service de Psychiatrie I, Hôpital Civil, Hôpitaux Universitaires de StrasbourgRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Active Comparator
Arm Label
patient with schizophrenia and periodic catatonia
patient with schizophrenia and hebephrenia
healthy volunteers
Arm Description
Outcomes
Primary Outcome Measures
Index of affect
Compare two groups of markers relating respectively to affectivity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation
Index of psychomotoricity
Compare two groups of markers relating to psychomotricity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation
Secondary Outcome Measures
Full Information
NCT ID
NCT03649581
First Posted
August 21, 2018
Last Updated
August 18, 2023
Sponsor
University Hospital, Strasbourg, France
1. Study Identification
Unique Protocol Identification Number
NCT03649581
Brief Title
Investigation of Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic Disorders
Acronym
NeuroSplitsz
Official Title
Investigation of Clinical, Cognitive and Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic Disorders
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 28, 2019 (Actual)
Primary Completion Date
February 2, 2027 (Anticipated)
Study Completion Date
February 2, 2027 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Strasbourg, France
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The current diagnostic criteria for schizophrenia and other psychotic disorders are relatively broad and lack precision. Therefore, distinct diseases may be grouped together under the same diagnostic category, although these diseases may differ according to their clinical expression, prognosis and perhaps their physiopathological causes.
We think that identifying subforms of psychotic disorders that are more homogeneous will better enable to understand their respective physiopathological causes and find personalized treatments.
This study will compare two subforms of psychotic disorders that have been clinically distinguished in the 1970s. These phenotypes have however not been validated yet using scientific investigations.
Using clinical assessments, cognitive evaluations and neurophysiological measures (fMRI) investigating the domains of affect and psychomotoricity , we expect that these two subforms will differ on their clinical, cognitive and neurophysiological characteristics, namely: hebephrenia will be associated with deficits on the affect markers , and respect psychomotoricity (catatonia scales, tests assessing movement planification) whereas the opposite pattern will be observed for periodic catatonia.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
84 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
patient with schizophrenia and periodic catatonia
Arm Type
Experimental
Arm Title
patient with schizophrenia and hebephrenia
Arm Type
Experimental
Arm Title
healthy volunteers
Arm Type
Active Comparator
Intervention Type
Other
Intervention Name(s)
compare the two groups of schizophrenic patients
Intervention Description
Compare two groups of markers relating respectively to psychomotricity and affectivity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation:
abnormalities of markers related to affectivity in Hebephrenia (with preservation of these markers in periodic catatonia),
abnormalities of markers related to psychomotricity in periodic catatonia (with markers of these tests in Hebephrenia).
Intervention Type
Other
Intervention Name(s)
compare the two groups of schizophrenic patients versus volunteers
Intervention Description
compare the results of the schizophrenic patient group with healthy volunteers
Primary Outcome Measure Information:
Title
Index of affect
Description
Compare two groups of markers relating respectively to affectivity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation
Time Frame
6 months after inclusion
Title
Index of psychomotoricity
Description
Compare two groups of markers relating to psychomotricity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation
Time Frame
6 months after inclusion
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
for both patients and controls
male or female willing to participate and who have signed up the legal document
under the protection of health insurance for patients only
schizophrenia or schizo-affective disorder according to the DSM-5 criteria
periodic catatonia or hebephrenia accordin to WKL classification
clinically stable for at least 2 months
in or out patients for controls only
no psychiatric history
Exclusion Criteria:
for both patients and controls
current severe or unstable somatic illness
neurological history (epilepsia, brain injury, brain surgery…)
current substance use disorder (DSM-5)
current major depressive disorder (DSM-5)
mental retardation (IQ < 70)
pregnancy, breast feeding
current legal control
contra-indication for fMRI for controls only psychotropic intake during the last 3 weeks
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Fabrice BERNA, MD
Phone
03 88 11 64 62
Email
fabrice.berna@chru-strasbourg.fr
Facility Information:
Facility Name
Service de Psychiatrie I, Hôpital Civil, Hôpitaux Universitaires de Strasbourg
City
Strasbourg
ZIP/Postal Code
67091
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fabrice BERNA, MD
Phone
33388116462
Email
fabrice.berna@chru-strasbourg.fr
First Name & Middle Initial & Last Name & Degree
Fabrice BERNA, MD
First Name & Middle Initial & Last Name & Degree
Jack FOUCHER, MD
First Name & Middle Initial & Last Name & Degree
Julie CLAUSS, MD
First Name & Middle Initial & Last Name & Degree
Olivier MAINBERGER, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Investigation of Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic Disorders
We'll reach out to this number within 24 hrs